Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): a prospective observational study in surgical patients

[1]  Mario Scalamogna,et al.  Alloantibody and Autoantibody Monitoring Predicts Islet Transplantation Outcome in Human Type 1 Diabetes , 2013, Diabetes.

[2]  C. Tseng.  Diabetes, insulin use, smoking, and pancreatic cancer mortality in Taiwan , 2013, Acta Diabetologica.

[3]  D. Mukhopadhyay,et al.  Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice. , 2012, Gastroenterology.

[4]  L. Piemonti,et al.  Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up , 2012, Acta Diabetologica.

[5]  V. Lemmens,et al.  Improving outcome for patients with pancreatic cancer through centralization , 2011, The British journal of surgery.

[6]  Jun Liu,et al.  Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. , 2011, European journal of cancer.

[7]  D. Andersen,et al.  Pancreatogenic Diabetes: Special Considerations for Management , 2011, Pancreatology.

[8]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[9]  D. Fine,et al.  The epidemiology and socioeconomic impact of chronic pancreatitis. , 2010, Best practice & research. Clinical gastroenterology.

[10]  A. Nicolucci.  Epidemiological aspects of neoplasms in diabetes , 2010, Acta Diabetologica.

[11]  R. Vigneri.  Diabetes: Diabetes therapy and cancer risk , 2009, Nature Reviews Endocrinology.

[12]  G. Lahat,et al.  Pancreatic incidentalomas: high rate of potentially malignant tumors. , 2009, Journal of the American College of Surgeons.

[13]  Mariza de Andrade,et al.  Temporal Association of Changes in Fasting Blood Glucose and Body Mass Index With Diagnosis of Pancreatic Cancer , 2009, The American Journal of Gastroenterology.

[14]  S. Haffner,et al.  Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. , 2008, Diabetes.

[15]  Ananda Basu,et al.  Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. , 2008, Gastroenterology.

[16]  E. Bosi,et al.  High Titer of Autoantibodies to GAD Identifies a Specific Phenotype of Adult-Onset Autoimmune Diabetes , 2007, Diabetes Care.

[17]  Joel G Fletcher,et al.  Resectability of Presymptomatic Pancreatic Cancer and Its Relationship to Onset of Diabetes: A Retrospective Review of CT Scans and Fasting Glucose Values Prior to Diagnosis , 2007, The American Journal of Gastroenterology.

[18]  P. Pucci,et al.  Pancreatic cancer-derived S-100A8 N-terminal peptide: a diabetes cause? , 2006, Clinica chimica acta; international journal of clinical chemistry.

[19]  Mariza de Andrade,et al.  Probability of pancreatic cancer following diabetes: a population-based study. , 2005, Gastroenterology.

[20]  M. Woodward,et al.  Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies , 2005, British Journal of Cancer.

[21]  J. Levy,et al.  Use and abuse of HOMA modeling. , 2004, Diabetes care.

[22]  J. Berré,et al.  Should pancreas imaging be recommanded in patients over 50 years when diabetes is discovered because of acute symptoms? , 2004, Diabetes & metabolism.

[23]  S. Kahn,et al.  The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes , 2003, Diabetologia.

[24]  J. Permert,et al.  The relationship between diabetes and pancreatic cancer , 2003, Molecular Cancer.

[25]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[26]  G. Gallus,et al.  Prevalence of NIDDM and impaired glucose tolerance in Italy: an OGTT-based population study , 1995, Diabetologia.

[27]  M. Plebani,et al.  Diabetes mellitus in pancreatic cancer follow-up. , 1994, Anticancer research.

[28]  L. Gullo,et al.  Diabetes and the risk of pancreatic cancer. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  T. Adrian,et al.  Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. , 1994, The New England journal of medicine.

[30]  L. Jorfeldt,et al.  Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer , 1993, The British journal of surgery.

[31]  P. Bennett,et al.  SEQUENTIAL CHANGES IN SERUM INSULIN CONCENTRATION DURING DEVELOPMENT OF NON-INSULIN-DEPENDENT DIABETES , 1989, The Lancet.

[32]  Jack Cuzick,et al.  Lancet Oncol 10 , 2013 .

[33]  S. Heymsfield,et al.  Type 2 Diabetes Mellitus: A Possible Surgically Reversible Intestinal Dysfunction , 2011, Obesity Surgery.

[34]  A. Basu,et al.  New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. , 2009, The Lancet. Oncology.

[35]  M. de Andrade,et al.  Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. , 2008, Gastroenterology.

[36]  H. Grosse.  [Diabetes and cancer]. , 1956, Deutsche Zeitschrift fur Verdauungs- und Stoffwechselkrankheiten.